Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Tria

In the SCALE trial (n=396), use of liraglutide 3mg as an adjunct to intensive behavioural therapy (IBT) in this population was associated with improved weight loss at 56 weeks (mean change of -5.8% vs -1.5% with placebo plus IBT; p<0.0001).

Source:

Diabetes Care